Trial Profile

A Multicenter Phase I Study of AIC100 CAR T Cells in Relapsed and/or Refractory Advanced Thyroid Cancer or Anaplastic Thyroid Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AIC 100 (Primary)
Indications Thyroid cancer
Focus Adverse reactions; First in man
Sponsors AffyImmune Therapeutics

Most Recent Events

30 Apr 2025 Results as of 12-Dec-2024 presented at the 116th Annual Meeting of the American Association for Cancer Research
28 Apr 2025 According to an AffyImmune Therapeutics Media Release, company will present data from this study at the American Association for Cancer Research (AACR) Annual Meeting, held April 25-30, 2025 at McCormick Place Convention Center in Chicago, IL.
30 Mar 2025 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com